# Epithalon (Epitalon): The Longevity Peptide That May Extend Your Telomeres
> Note: PeptIQ is not a medical provider. The information in this article is for educational purposes only. Always consult a qualified healthcare professional before starting any peptide protocol.
Epithalon — also spelled Epitalon — is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It has one of the longest research histories of any longevity peptide, with animal and human studies going back to the 1980s. The core mechanism is compelling: Epithalon activates telomerase, the enzyme that lengthens telomeres, which are the protective caps on your DNA that shorten every time a cell divides.
Shorter telomeres correlate with accelerated aging, cardiovascular disease, cancer risk, and earlier mortality. Epithalon's ability to counteract that shortening puts it in a different category from most anti-aging compounds.
The Science Behind Telomeres and Telomerase
Every time a cell divides, its telomeres shorten slightly. When telomeres get critically short, the cell either enters senescence (stops dividing, becomes inflammatory) or apoptosis (dies). This process is fundamental to biological aging.
Telomerase is the enzyme that rebuilds telomere length. In most adult somatic cells, telomerase activity is very low — which is why cells age. Stem cells and certain immune cells maintain higher telomerase activity, and this is central to their regenerative capacity.
Epithalon stimulates telomerase production, which in turn helps restore telomere length. A landmark 2003 study by Khavinson et al. demonstrated that Epithalon increased telomerase activity in human somatic cells and extended their functional lifespan in vitro. Follow-up animal studies showed extended lifespan, reduced tumor incidence, and improved hormonal function in aged animals.
Key Mechanisms
Telomerase activation: The primary mechanism. Epithalon stimulates telomerase, enabling cells to maintain longer telomeres and continue dividing without entering premature senescence.
Melatonin regulation: Epithalon increases melatonin production from the pineal gland. Melatonin production declines sharply with age, and this decline is linked to disrupted sleep cycles, reduced antioxidant capacity, and accelerated aging. Restoring melatonin signaling is one of the more underappreciated effects of Epithalon.
Antioxidant activity: Epithalon reduces oxidative stress markers and lipid peroxidation, both of which drive cellular aging. Khavinson's research showed reductions in 8-OHdG (a DNA oxidation marker) in treated animals.
Hormonal restoration: Animal data shows improvements in LH, FSH, and sex hormone levels with Epithalon treatment in aged subjects. This aligns with its pineal gland effects and suggests broad endocrine benefits.
Tumor suppression: Long-term animal studies found reduced spontaneous tumor development in Epithalon-treated groups compared to controls. The mechanism appears to involve both telomere stabilization and improved immune surveillance.
What the Human Data Shows
Epithalon has been studied in humans, primarily elderly populations in Russian clinical trials. Key findings:
- Improved cardiovascular function and reduced atherosclerotic markers
- Restored circadian rhythm and melatonin secretion in elderly subjects
- Improved retinal function in patients with age-related retinal degeneration
- Enhanced immune function and T-cell activity
- Extended average lifespan in a 15-year follow-up study comparing treated vs. control elderly patients
The human research is not as extensive as we'd want from a Western regulatory standpoint — most trials were conducted in Russia and the sample sizes were modest. That said, the consistency across multiple studies and the plausibility of the mechanism make Epithalon one of the better-supported longevity peptides available.
Dosing Protocols
Epithalon is administered by subcutaneous or intramuscular injection. Intranasal administration has also been explored, with good bioavailability reported.
Typical Dosing Range
| Protocol | Dose | Frequency | Cycle Length |
|---|---|---|---|
| Conservative | 5 mg/day | Daily | 10 days |
| Standard | 10 mg/day | Daily | 10–20 days |
| Intensive | 10 mg twice/day | Daily | 10 days |
| Maintenance | 5–10 mg/day | Every other day | Ongoing |
Recommended Starting Protocol
Cycle length: 10 to 20 consecutive days
Dose: 5–10 mg per day, subcutaneous injection
Frequency of cycles: 1–2 cycles per year is the most commonly cited approach for longevity purposes. Some practitioners run 3–4 shorter cycles annually.
Most of the Khavinson clinical data used 10-day courses. Running Epithalon continuously is not standard practice — the cyclical approach mimics how the research was conducted and avoids potential receptor desensitization.
> Example only, not your vial. The figures below are worked examples for a labeled vial size and diluent volume. A different mass or water volume changes every unit count. Check your label and run the reconstitution calculator.
Reconstitution (example only): Educational write-ups use bacteriostatic water. One worked example: a labeled 10 mg vial with 2 mL BAC water → 5 mg/mL, so a 1 mL draw is 5 mg. That is concentration arithmetic, not a recommended mix or protocol.